What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Breast cancer
Patrick Neven focuses on Breast cancer, Internal medicine, Oncology, Gynecology and Tamoxifen.
His research on Breast cancer concerns the broader Cancer.
His Internal medicine study combines topics from a wide range of disciplines, such as Placebo and Endocrinology.
His Oncology research is multidisciplinary, relying on both Adenocarcinoma, Endocrine system, Estrogen receptor and Pathology.
He has included themes like Pregnancy, Cohort study, Anastrozole, Predictive value of tests and Proportional hazards model in his Gynecology study.
His studies examine the connections between Tamoxifen and genetics, as well as such issues in Endometrium, with regards to Uterus, Hysteroscopy and DNA damage.
His most cited work include:
- Association analysis identifies 65 new breast cancer risk loci (569 citations)
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. (536 citations)
- Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies (502 citations)
What are the main themes of his work throughout his whole career to date?
Patrick Neven spends much of his time researching Internal medicine, Breast cancer, Oncology, Cancer and Tamoxifen.
Internal medicine is a component of his Estrogen receptor, Chemotherapy, Aromatase inhibitor, Letrozole and Metastatic breast cancer studies.
In his research, Debulking and Ovarian cancer is intimately related to Surgery, which falls under the overarching field of Breast cancer.
His work is dedicated to discovering how Oncology, Exemestane are connected with Everolimus and other disciplines.
His Cancer study combines topics in areas such as Placebo and Clinical endpoint.
The concepts of his Tamoxifen study are interwoven with issues in Endometrium, Endocrinology, Aromatase and Prospective cohort study.
He most often published in these fields:
- Internal medicine (64.58%)
- Breast cancer (58.63%)
- Oncology (52.83%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (64.58%)
- Oncology (52.83%)
- Breast cancer (58.63%)
In recent papers he was focusing on the following fields of study:
Patrick Neven mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer.
In his study, Progressive disease is strongly linked to Gastroenterology, which falls under the umbrella field of Internal medicine.
His research investigates the connection with Oncology and areas like Abemaciclib which intersect with concerns in Early breast cancer.
His research in Breast cancer is mostly concerned with Tamoxifen.
His Cancer research incorporates themes from Biomarker and Estrogen.
Patrick Neven has researched Metastatic breast cancer in several fields, including Cancer research, Trastuzumab and Phases of clinical research.
Between 2019 and 2021, his most popular works were:
- Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. (23 citations)
- Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. (16 citations)
- Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen (10 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
His scientific interests lie mostly in Internal medicine, Breast cancer, Oncology, Cancer and Fulvestrant.
His study explores the link between Internal medicine and topics such as Gastroenterology that cross with problems in Progressive disease.
Patrick Neven works in the field of Breast cancer, focusing on Estrogen receptor in particular.
The various areas that Patrick Neven examines in his Oncology study include Tamoxifen, Proportional hazards model, MSH2, CYP2D6 and MSH6.
His work in Cancer addresses issues such as Biomarker, which are connected to fields such as Estrogen.
His Fulvestrant study integrates concerns from other disciplines, such as Brief Pain Inventory, Aromatase inhibitor, Placebo and Hormone receptor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
